GlassScriptPhysician profile
Thomas P Molton
NPI 1144636648
$656.00
in general payments reported to CMS, 2019-2025
18 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.54 · 2024: $326 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.50 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $80.70 | 2023-2025 | Carvykti, Darzalex |
| Regeneron Healthcare Solutions, INC. | $68.32 | 2024-2025 | Libtayo, Lynozyfic |
| Novartis Pharmaceuticals Corporation | $56.51 | 2024 | |
| Stemline Therapeutics INC. | $55.68 | 2024 | Orserdu |
| Kyowa Kirin, INC. | $47.71 | 2024 | Poteligeo |
| Astrazeneca Pharmaceuticals LP | $47.22 | 2025 | Lynparza |
| Abbvie INC. | $32.50 | 2025 | |
| Genmab U.S., INC. | $32.23 | 2024 | Tivdak |
| Glaxosmithkline, LLC. | $31.24 | 2024-2025 | Jemperli, Ojjaara |
| Celgene Corporation | $30.45 | 2025 | Reblozyl |
| Blueprint Medicines Corporation | $28.87 | 2024 | Ayvakit |
| Pfizer INC. | $23.89 | 2025 | |
| Karyopharm Therapeutics INC. | $23.44 | 2025 | Xpovio |
| Beone Medicines USA, INC. | $21.49 | 2025 | Tevimbra |
| Adaptive Biotechnologies Corporation | $21.23 | 2024 | Clonoseq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $20.91 | 2025 | Mektovi, Braftovi, Xalkori |
| Genzyme Corporation | $17.75 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2025 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Molton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.